Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M65.4Revenue $M--Net Margin (%)--Altman Z-Score7.8
Enterprise Value $M-21.9EPS $-2.7Operating Margin %--Piotroski F-Score--
P/E(ttm)--Beneish M-Score--Pre-tax Margin (%)--Higher ROA y-yN
Price/Book0.810-y EBITDA Growth Rate %--Quick Ratio19.8Cash flow > EarningsN
Price/Sales--5-y EBITDA Growth Rate %--Current Ratio19.8Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-33.8Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-49.1Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M15.5ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with NVLS

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
NVLSJulian Robertson 2015-09-30 Buy 1.13%$12.74 - $20.16
($16.43)
$ 4.23-74%New holding650,915
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

NVLS is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


NVLS: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Congleton JonPresident and CEO 2016-03-24Buy5,000$4.220.24view
Congleton JonPresident and CEO 2016-03-22Buy5,000$4.38-3.42view
Congleton JonPresident and CEO 2015-12-11Buy5,000$8.1-47.78view
CONWAY ROBERT EDirector 2015-12-09Buy10,000$8.1-47.78view
Flynn James E 2015-06-23Buy250,000$14-69.79view
Hawkes Bay Master Investors (C10% Owner 2015-06-22Buy17,200$14.69-71.2view
Rock Springs Capital Managemen10% Owner 2015-06-22Buy200,000$14-69.79view
Hawkes Bay Master Investors (C10% Owner 2015-06-18Buy20,400$14.47-70.77view
Jennison Global Healthcare Mas10% Owner 2015-06-17Buy26,149$14-69.79view
GOTTLIEB ANDREWVP and General Counsel 2012-04-16Sell3,488$47.37-91.07view

Quarterly/Annual Reports about NVLS:

News about NVLS:

Articles On GuruFocus.com
No related article found.

More From Other Websites
NIVALIS THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other... Apr 22 2016
Nivalis Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Apr 22 2016
Nivalis Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Apr 22 2016
Nivalis Therapeutics Names David Rodman As Chief Medical Officer Apr 18 2016
Nivalis Therapeutics Appoints David Rodman, MD as Chief Medical Officer and Executive Vice President... Apr 18 2016
Nivalis Therapeutics Appoints David Rodman, MD as Chief Medical Officer and Executive Vice President... Apr 18 2016
NIVALIS THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Apr 05 2016
Nivalis Therapeutics Reaches 50 Percent Enrollment Milestone in Phase 2 Clinical Trial in Cystic... Apr 05 2016
Nivalis Therapeutics Reaches 50 Percent Enrollment Milestone in Phase 2 Clinical Trial in Cystic... Apr 05 2016
Need for Patient-Centric Clinical Trials Fuels Adoption of Greenphire's ClinCard Solution Apr 05 2016
NIVALIS THERAPEUTICS, INC. Financials Mar 12 2016
NIVALIS THERAPEUTICS, INC. Files SEC form 10-K, Annual Report Mar 08 2016
Nivalis (NVLS) Provides Update on Cystic Fibrosis Candidate Mar 08 2016
NIVALIS THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Mar 07 2016
Nivalis Therapeutics Expands N91115 Clinical Development Program in Cystic Fibrosis Mar 07 2016
Nivalis Therapeutics to Present at Two Upcoming Investor Conferences Mar 02 2016
NIVALIS THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial... Mar 01 2016
Nivalis Therapeutics Announces Appointment of Paul Sekhri to Its Board of Directors Mar 01 2016
NIVALIS THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Feb 29 2016
Nivalis Therapeutics reports 4Q loss Feb 29 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)